Q-omics provides the consensus-scored TBX20 profile across patient tissues and cancer cell-line models. TBX20 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, TBX20 is differentially expressed in 13, with the highest sampling consensus in BLCA. Additionally, TBX20 RNA expression shows 15,185 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRP, BLCA, and UVM as cancer lineages where TBX20 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TBX20 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TBX20 survival associations across molecular data types. TBX20 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TBX20 RNA expression–survival associations across cancer types. High TBX20 expression shows unfavorable associations in KIRP, UVM, MESO, OV and LGG, but favorable associations in READ. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for TBX20 RNA expression.
This table summarizes TBX20 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for TBX20. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TBX20 shows lower tumor expression in BLCA and higher tumor expression in UCEC, COAD, BRCA, LUSC and KIRP. The BLCA box plot shows higher TBX20 RNA expression in normal versus tumor tissue (log2 FC = −2.425, t-test p = .001).
This table shows molecular features associated with TBX20 in patient tissues and cancer cell lines. In patient samples, TBX20 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, TBX20 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in BONE and SOFT_TISSUE.
